All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Ivabradine in stable coronary artery disease without clinical heart failure.

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F14%3A33152278" target="_blank" >RIV/61989592:15110/14:33152278 - isvavai.cz</a>

  • Alternative codes found

    RIV/00843989:_____/14:E0106093

  • Result on the web

    <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1406430#t=articleTop" target="_blank" >http://www.nejm.org/doi/full/10.1056/NEJMoa1406430#t=articleTop</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1056/NEJMoa1406430" target="_blank" >10.1056/NEJMoa1406430</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Ivabradine in stable coronary artery disease without clinical heart failure.

  • Original language description

    An elevated heart rate is an established marker of cardiovascular risk. Previous analyses have suggested that ivabradine, a heart-rate-reducing agent, may improve outcomes in patients with stable coronary artery disease, left ventricular dysfunction, anda heart rate of 70 beats per minute or more. We conducted a randomized, double-blind, placebo-controlled trial of ivabradine, added to standard background therapy, in 19,102 patients who had both stable coronary artery disease without clinical heart failure and a heart rate of 70 beats per minute or more We randomly assigned patients to placebo or ivabradine, at a dose of up to 10 mg twice daily, with the dose adjusted to achieve a target heart rate of 55 to 60 beats per minute. The primary end point was a composite of death from cardiovascular causes or nonfatal myocardial infarction.At 3 months, the mean (+-SD) heart rate of the patients was 60.7+-9.0 beats per minute in the ivabradine group versus 70.6+-10.1 beats per minute in the

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FA - Cardiovascular diseases including cardio-surgery

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2014

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    New England Journal of Medicine

  • ISSN

    0028-4793

  • e-ISSN

  • Volume of the periodical

    371

  • Issue of the periodical within the volume

    12

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    9

  • Pages from-to

    1091-1099

  • UT code for WoS article

    000341687300004

  • EID of the result in the Scopus database